Agomelatine for the treatment of major depressive disorder

Bibliography

• Kessler RC, Berglund P, Demler O, The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009;19:34-40
   PubMed Web of Science ®Google Scholar
• Berlim MT, Fleck MP, Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med 2008;40:149-59
   PubMed Web of Science ®Google Scholar
• Casacalenda N, Perry JC, Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry 2002;159:1354-60
   PubMed Web of Science ®Google Scholar
• Hollon SD, DeRubeis RJ, Shelton RC, Prevention of relapse following cognitive therapy versus medications in moderate to severe depression. Arch Gen Psychiatry 2005;62:417-22
   PubMed Web of Science ®Google Scholar
• Mueller TI, Leon AC, Keller MB, Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156:1000-6
   PubMed Web of Science ®Google Scholar
• Depression Guideline Panel. Treatment of major depression. Depression in Primary Care. Clinical Practice Guideline No. 5. US Dept of Health and Human Services, Public Health Service, and Agency for Health Care Policy and Research, Rockville, MD. Volume 2 AHCPR publication; 1993. p. 93-0550
   Google Scholar
• Ferguson SA, Rajaratnam SM, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother 2010;10:305-18
   PubMed Web of Science ®Google Scholar
• Bunney WE, Bunney BG. Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology 2000;22:335-45
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circadian basis of winter depression. Proc Natl Acad Sci USA 2006;103:7414-19
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16:93-100
   PubMed Web of Science ®Google Scholar
• Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73
   PubMed Web of Science ®Google Scholar
• Stahl SM, Fava M, Trivedi MH, Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71:616-26
   PubMed Web of Science ®Google Scholar
• Hale A, Corral RM, Mencacci C, Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010;25:305-14
   PubMed Web of Science ®Google Scholar
• Zajecka J, Schatzberg A, Stahl S, Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30:135-44
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-33
   PubMed Web of Science ®Google Scholar
• Kasper S, Hajak G, Wulff K, Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010;71:109-20
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007;22:283-91
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Emsley R, Rembry S, Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:1128-37
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:561-6
   PubMed Web of Science ®Google Scholar
• Sartorius N, Baghai TC, Baldwin DS, Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol 2007;10:S1-207
   Web of Science ®Google Scholar
• Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 2006;67(Suppl 4):3-7
   PubMed Web of Science ®Google Scholar
• Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009;6:53-77
   PubMed Web of Science ®Google Scholar
• Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res 2008;42:791-6
   PubMed Web of Science ®Google Scholar
• Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One 2009;4:e4824
   PubMed Web of Science ®Google Scholar
• Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother 2008;42:1822-31
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64
   PubMed Web of Science ®Google Scholar
• Krauchi K, Cajochen C, Mori D, Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997;272:R1178-88
   PubMed Web of Science ®Google Scholar
• Lemoine R, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-32
   PubMed Web of Science ®Google Scholar
• Quera-Salva MA, Vanier B, Laredo J, Major depressive disorder, sleep EEG, and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007;10:661-73
   PubMed Web of Science ®Google Scholar
• Leproult R, Van OA, L'Hermite-Baleriaux M, Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol 2005;63:298-304
   PubMed Web of Science ®Google Scholar
• Pjrek E, Winkler D, Konstantinidis A, Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl) 2006;190:575-9
   PubMed Web of Science ®Google Scholar
• Depreux P, Lesieur D, Mansour HA, Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J Med Chem 1994;37:3231-9
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics. European Medicines Agency. European Public Assessment Report, Agomelatine, 23 September 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EP AR_-_Product_Information/human/000915/WC500046227.pdf [Last accessed 6 January 2011]
   Google Scholar
• Ying SW, Rusak B, Delagrange P, Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur J Pharmacol 1996;296:33
   PubMed Web of Science ®Google Scholar
• Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005;177:448-58
   PubMed Web of Science ®Google Scholar
• Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat 2009;5:563-76
   PubMed Web of Science ®Google Scholar
• Deussing JM. Animal models of depression. Drug Discov Today 2006;3:375-83
   Google Scholar
• Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs 2009;23
   PubMed Web of Science ®Google Scholar
• de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010;9:628-42
   PubMed Web of Science ®Google Scholar
• Fournier JC, DeRubeis RJ, Hollon SD, Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53
   PubMed Web of Science ®Google Scholar
• Eser D, Baghai TC, Moller HJ. Agomelatine: the evidence for its place in the treatment of depression. Core Evid 2010;4:171-9
   PubMedGoogle Scholar
• Cymbalta™. U.S. Package Insert. Eli Lilly & Co., 2004
   Google Scholar
• Weber J, Siddiqui MA, Wagstaff AJ, McCormack PL. Low-dose doxepin: in the treatment of insomnia. CNS Drugs 2010;24:713-20
   PubMed Web of Science ®Google Scholar
• Serfaty MA, Osborne D, Buszewicz MJ, A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol 2010;25:132-42
   PubMed Web of Science ®Google Scholar
• Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006;20:981-92
   PubMed Web of Science ®Google Scholar
• Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs 2010;24:131-61
   PubMed Web of Science ®Google Scholar
• Komossa K, Depping AM, Gaudchau A, Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010;12:CD008121
   PubMed Web of Science ®Google Scholar
• Tecott LH, Sun LM, Akana SF, Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995;374:542-6
   PubMed Web of Science ®Google Scholar
• Bobo WV, Shelton RC. Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. Expert Rev Neurother 2010;10:651-70
   PubMed Web of Science ®Google Scholar